Radiobiological effectiveness of laser accelerated electrons in comparison to electron beams from a conventional linear accelerator.
The notable progress in laser particle acceleration technology promises potential medical application in cancer therapy through compact and cost effective laser devices that are suitable for already existing clinics. Previously, consequences on the radiobiological response by laser driven particle beams characterised by an ultra high peak dose rate have to be investigated. Therefore, tumour and non-malignant cells were irradiated with pulsed laser accelerated electrons at the JETI facility for the comparison with continuous electrons of a conventional therapy LINAC. Dose response curves were measured for the biological endpoints clonogenic survival and residual DNA double strand breaks. The overall results show no significant differences in radiobiological response for in vitro cell experiments between laser accelerated pulsed and clinical used electron beams. These first systematic in vitro cell response studies with precise dosimetry to laser driven electron beams represent a first step toward the long term aim of the application of laser accelerated particles in radiotherapy.
OncoRay - National Center for Radiation Research in Oncology, Medical Faculty Carl Gustav Carus, Technische Universität, Dresden, Germany. lydia.laschinsky@oncoray.de
Lydia
L
Laschinsky
Michael
M
Baumann
Elke
E
Beyreuther
Wolfgang
W
Enghardt
Malte
M
Kaluza
Leonhard
L
Karsch
Elisabeth
E
Lessmann
Doreen
D
Naumburger
Maria
M
Nicolai
Christian
C
Richter
Roland
R
Sauerbrey
Hans-Peter
HP
Schlenvoigt
Jörg
J
Pawelke
D002460:Cell Line; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000528:radiation effects; D053903:DNA Breaks, Double-Stranded; D004307:Dose-Response Relationship, Radiation; D004583:Electrons / Q000627:therapeutic use*; D004867:Equipment Design; D006801:Humans; D053685:Laser Therapy / Q000295:instrumentation; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy*; D010315:Particle Accelerators / Q000295:instrumentation; D012062:Relative Biological Effectiveness; D014410:Tumor Stem Cell Assay